| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and… | Non Small Cell Lung Cancer | Recruiting |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in… | Non-Small Cell Lung Cancer | Recruiting |
| NCT03820830 | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast… | Breast Cancer Recurrent | Active, Not Recruiting |
| Phase 2 | |||
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease… | SCLC,Extensive Stage | Recruiting |
| NCT07203053 | A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer… | Extensive Stage Lung Small Cell Cancer | Recruiting |
| NCT05601973 | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03965468 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT05673187 | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance… | NSCLC Stage IV | Active, Not Recruiting |
| Not specified | |||
| NCT02308085 | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive… | Early Breast Cancer | Active, Not Recruiting |